Boston Scientific touts CMS reimbursement nod for asthma treatment | Regulatory Roundup


Boston Scientific Corp.’s (NYSE:BSX) Alair asthma management system won reimbursement from the Centers for Medicare & Medicaid Services, effective at the start of this year.

The Alair system delivers precise thermal energy lung to tissue via bronchoscope to reduce excessively smooth muscle, decreasing the airway’s ability to constrict.

The federal agency granted the Alair device approval for Medicare reimbursement through a separate "pass-through" payment when the procedure is performed in outpatient settings, the Natick, Mass.-based med-tech titan announced.

Sign up to get our free newsletters delivered right to your inbox

The approval allows hospitals to receive payment for the Alair catheter in addition to Medicare payment for the bronchial thermoplasty procedure, according to a press release.

"CMS’ decision that the Alair bronchial thermoplasty system meets the criteria for transitional pass-through payment is a very positive development for severe asthmatics and the pulmonary physician community," BSX endoscopy division president David Pierce said in prepared remarks."It supports what we have confirmed through our clinical trials:  bronchial thermoplasty offers a new advancement in the treatment of patients with severe asthma who are not well controlled despite taking recommended doses of asthma medications.  This decision also sets an important precedent for health care payers throughout the United States."

Boston Scientific added the Alair system to its portfolio when it acquired Asthmatx Inc. for $194 million in Sept. 2010. Alair won FDA approval in April 2010, becoming the first device-based asthma treatment approved by the watchdog agency.

Regulatory Roundup

BioMimetic’s bone graft PMA gets a no-go from the FDA
The federal watchdog agency did not approve the pre-market approval application for BioMimetic Therapeutics’ Augment bone graft, even after an independent advisory panel voted in the product’s favor. Read more

AirStrip lands CE Mark for mobile monitoring system
San Antonio, Texas-based AirStrip Technologies won CE Mark approval for its flagship mobile patient monitoring systems. The AirStrip OB, AirStrip Cardiology and AirStrip Patient Monitoring systems are all available for use by European clinicians. Read more

Ultrasound stroke treatment wins CE Mark
Cerevast Therapeutics landed CE Mark approval for its Clotbust ER SonoLysis system to treat ischemic stroke in emergency settings. Read more

FDA approves Cyberonics AspireHC generator
The federal watchdog agency cleared the re-design of Cyberonics Inc.’s AspireHC generator. The VNS therapy treatment was the subject of a voluntary recall in August 2011. Read more

Enteromedics completes enrollment of clinical trials
St. Paul, Minn.-based Enteromedics completed patient enrollment of the ReCharge trial for its VBloc vagal blocking therapy. The random, double-blind, parallel-group study will consist of 233 patients in the U.S. and Australia. Read more

ThermoGenesis wins approval in India
ThermoGenesis Corp. landed approval from India’s Ministry of Health for its AutoXpress system for the processing of stem cells from cord blood. Read more

BioLineRx initiates registration trial for BCM
Biopharmaceutical development company BioLineRx initiated the CE mark registration trial of its BCM (BL-1040) system, a medical device to prevent cardiac remodeling following acute myocardial infarctions. Read more

RSS From Medical Design & Outsourcing

  • Athermal laser machining cuts bioabsorbable polymers and more
    A the recent MD&M East trade show in New York, Norman Noble, discussed the capability of athermal laser manufacturer. The company has developed the Noble S.T.E.A.L.T.H. (System To Enable Ablation Laser Technology Haz-free). The athermal laser machining process was developed to create precise features in any material, including bioabsorbable polymers, shape memory metals and other […]
  • Exciting possibilities for metallic glass in the medical device world
    Researchers are exploring the potential of metallic glass as a versatile, pliable material that is stronger than steel, with a bevy of possible medical device applications. Yale University engineers have discovered a unique method for designing metallic glass nanostructures across a wide range of chemicals, a technique that could have applications for everything from watch […]
  • Strong Precision Technologies’ medical divisions to unify under MedTorque brand
    Strong Precision Technologies announced on July 2, 2015, that its two medical divisions will now go to market under a single brand, MedTorque. The move reflects the increasing integration of the division formerly known as Inland Midwest with MedTorque, its sister division in Kenosha, WI. “We will continue providing our customers with the personalized level of service […]
  • Olympus offers next-day product replacement guarantee for medical devices
    Olympus, a medical and surgical procedures solutions company, announced that it is guaranteeing next-day replacements for surgical equipment at no additional charge. Olympus is the first surgical product manufacturer to offer this type of guarantee. The service became available to customers with an Olympus Full Service Agreement earlier this year. “Canceled procedures can be costly for healthcare facilities […]
  • More accurate prediction on prognosis in multiple myeloma from SkylineDx
    SkylineDx, a biotechnology company specializing in the development and commercialization of genetic tests, is launching its MMprofiler assay. This test enables clinicians to more accurately predict the prognosis of patients with multiple myeloma (bone marrow cancer) than traditional methods. The MMprofiler measures the activity of 92 genes which are directly or indirectly related to the […]
  • Flint Mobile swaps card reader for camera, accept mobile payments anywhere
    Flint Mobile, the swipe-free mobile payments app, has significantly expanded its payment management and loyalty capabilities for small, service-centric businesses, like the ones run by on-the-go medical equipment professionals. The toggle-free mobile technology makes the process quite simple for both parties, as all transactions are conducted through the mobile device’s camera without the need of any external […]
  • Should scientists be allowed to genetically alter human embryos?
    Scientists have at their disposal, a way to explore the possible prevention of genetic diseases before birth. But should they? Currently, the most promising path forward involves editing the genes of human embryos, a procedure threaded with controversy. An article in “Chemical & Engineering News” (C&EN), the weekly newsmagazine of the American Chemical Society (ACS), parses […]
  • Tackling chronic sinusitis by addressing underlying factors
    The stuffy noses and sinus pressure of head colds are uncomfortable, but for most people, they go away within days. For those with chronic sinusitis, however, those symptoms and others drag on for weeks. Now scientists are onto a potential new therapy that could address one of the underlying factors associated with the condition. They […]
  • Implantable “artificial pancreas” could help diabetes patients control their blood sugar
    Living with Type 1 diabetes requires constant monitoring of blood sugar levels and injecting insulin daily. Now scientists are reporting in the American Chemical Society (ACS) journal, “Industrial & Engineering Chemistry Research,” the development of an implantable “artificial pancreas” that continuously measures a person’s blood sugar or glucose level and can automatically release insulin as […]
  • Drug Deactivation program roll out to all facilities for safe disposal of unused prescription medications
    Verde Technologies announced that New Brighton-based Meridian Behavioral Health, the largest for-profit substance abuse and addiction treatment group in Minnesota, has become its most recent partner in the deactivation and safe disposal of prescription medications including methadone. Meridian is the first behavioral health group to roll out the Deterra Drug Deactivation System to all 17 […]
  • Lophius Biosciences introduces T-activated ImmunoScan Cocktail
    Lophius Biosciences announced the commercial launch of T-Track ImmunoScan and T-activated ImmunoScan Cocktail. Based on a proprietary and very specific cocktail of stimulants in combination with the Company’s T-activation technology, T-Track ImmunoScan and T-activated ImmunoScan Cocktail specifically target different cell types involved in both the adaptive and innate immune system. T-Track ImmunoScan and the T-activated […]

Leave a Reply